Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Uses reduces hives and relieves itching due to hives (urticaria). This product will not prevent hives or an allergic skin reaction from occurring. FDA label
Fexofenadine · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Fexofenadine Tablets 180 mg |
| 2 | ACTIVE_COMPARATOR | Allegra® Tablets 180 mg |
| Name | Type | Description |
|---|---|---|
| Fexofenadine Tablets 180 mg | DRUG | 180mg, single dose fed |
| Allegra® Tablets 180 mg | DRUG | 180mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening...
Fexofenadine is a small molecule drug developed by Viatris Inc. (ticker VTRS). It is an HRH1 antagonist. The specific indications for this asset are undisclosed. It has been studied in Phase 1 clinical trials involving healthy volunteers.
Fexofenadine targets HRH1, the histamine H1 receptor. It acts as an antagonist at this receptor. This mechanism is consistent with its classification as an antihistamine small molecule.
Fexofenadine is developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the company responsible for the development of this asset.
Fexofenadine is in Phase 1 clinical development. It is investigational and has not been approved by the FDA for any indication. The program includes two completed Phase 1 trials.
Fexofenadine has been evaluated in two completed Phase 1 trials: NCT00649376, a fasting study with 68 healthy volunteers, and NCT00647985, a food study with 28 healthy volunteers. Both were conducted in the United States and were active-controlled.